Rezulin Class Action Lawsuit
The Kahn Gauthier Law Group is investigating any possible lawsuit against drug manufacturer Pfizer to recover for injuries suffered by users of the now-withdrawn diabetes medication Rezulin (troglitazone). Rezulin was prescribed for type 2, or non-insulin dependent, diabetes patients who had not responded to other therapies. This type of diabetes typically is found in adults.
Rezulin was approved for use in the U.S. in January, 1997 after ‘fast-track’ approval by the FDA. The first medical examiner for the FDA who investigated the drug concluded that it was too dangerous to approve. He was stripped of the assignment, and his report was purged from agency files and withheld from an FDA advisory committee.
Finally, on March 21, 2000, Rezulin was withdrawn from the U.S. market. The FDA has estimated that two million people used Rezulin.
When Rezulin was approved, the manufacturer’s chief executive told investors he saw it as a ‘billion-dollar blockbuster.’ In fact, in three years on the market, Rezulin generated more than $2 billion in sales.